Prevalence, nature and potential preventability of adverse drug events - A population-based medical record study of 4970 adults

British Journal of Clinical Pharmacology

Volumn 78, Issue 1, 2014, Pages 170-183

  Hakkarainen, Katja M ^a,b   Gyllensten, Hanna ^a,b   Jönsson, Anna K ^c,d   Andersson Sundell, Karolina ^b   Petzold, Max ^e   Hägg, Staffan ^c,d,f  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f Jonkoping County Council   (Sweden)

Author keywords

adverse drug event; medical records; medication error; pharmacoepidemiology; prevalence

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; DIURETIC AGENT; NEUROLEPTIC AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; DIZZINESS; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG INTOXICATION; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MORBIDITY; MUSCULOSKELETAL DISEASE; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT SAFETY; PREVALENCE; PREVENTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOM SAMPLE; RISK ASSESSMENT; SUBTHERAPEUTIC EFFECT; VASCULAR DISEASE; WEIGHT GAIN; ADOLESCENT; AGE; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MEDICAL RECORD; MEDICATION ERROR; MIDDLE AGED; PREVENTION AND CONTROL; REGISTER; STATISTICS AND NUMERICAL DATA; SWEDEN; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MEDICATION ERRORS; MIDDLE AGED; PREVALENCE; REGISTRIES; SWEDEN; YOUNG ADULT;

EID: 84902989191     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12314     Document Type: Article

References (76)

1. Department of Health. Safety First: A Report for Patients, Clinicians and Healthcare Managers. London: Department of Health, 2006.
2. World Health Organization. WHO Patient Safety Research-Better Knowledge for Safer Care. Geneva: World Health Organization, 2009.
3. European Medicines Agency. Medication-Errors Workshop Report. London: European Medicines Agency, 2013.
4. Ministry of Health and Social Affairs. National Medication Strategy. [in Swedish], Stockholm: Ministry of Health and Social Affairs, 2011.
5. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R,. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29-34.
6. Leendertse AJ, Visser D, Egberts AC, van den Bemt PM,. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf 2010; 33: 233-244.
7. Aronson JK, Ferner RE,. Clarification of terminology in drug safety. Drug Saf 2005; 28: 851-870.
8. Krähenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbuhl S,. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007; 30: 379-407.
9. Tache SV, Sonnichsen A, Ashcroft DM,. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother 2011; 45: 977-989.
10. Winterstein AG, Sauer BC, Hepler CD, Poole C,. Preventable drug-related hospital admissions. Ann Pharmacother 2002; 36: 1238-1248.
11. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R,. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003; 60: 1750-1759.
12. Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A,. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007; 41: 1411-1426.
13. Cano FG, Rozenfeld S,. Adverse drug events in hospitals: a systematic review. Cad Saude Publica 2009; 25: (Suppl. 3): S360-372.
14. Hakkarainen KM, Hedna K, Petzold M, Hägg S,. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions-a meta-analysis. PLoS ONE 2012; 7: e33236.
15. Isacson D, Johansson L, Bingefors K,. Nationwide survey of subjectively reported adverse drug reactions in Sweden. Ann Pharmacother 2008; 42: 347-353.
16. Weingart SN, Gandhi TK, Seger AC, Seger DL, Borus J, Burdick E, Leape LL, Bates DW,. Patient-reported medication symptoms in primary care. Arch Intern Med 2005; 165: 234-240.
17. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW,. Adverse drug events in ambulatory care. N Engl J Med 2003; 348: 1556-1564.
18. Chrischilles EA, Segar ET, Wallace RB,. Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older. Ann Intern Med 1992; 117: 634-640.
19. Hutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HH,. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis 1986; 39: 533-542.
20. Oladimeji O, Farris KB, Urmie JG, Doucette WR,. Risk factors for self-reported adverse drug events among Medicare enrollees. Ann Pharmacother 2008; 42: 53-61.
21. Gandhi TK, Burstin HR, Cook EF, Puopolo AL, Haas JS, Brennan TA, Bates DW,. Drug complications in outpatients. J Gen Intern Med 2000; 15: 149-154.
22. Green JL, Hawley JN, Rask KJ,. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother 2007; 5: 31-39.
23. Chrischilles E, Rubenstein L, Van Gilder R, Voelker M, Wright K, Wallace R,. Risk factors for adverse drug events in older adults with mobility limitations in the community setting. J Am Geriatr Soc 2007; 55: 29-34.
24. Shiyanbola OO, Farris KB,. Concerns and beliefs about medicines and inappropriate medications: an Internet-based survey on risk factors for self-reported adverse drug events among older adults. Am J Geriatr Pharmacother 2010; 8: 245-257.
25. Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S,. Prevalence and perceived preventability of self-reported adverse drug events-a population-based survey of 7099 adults. PLoS ONE 2013; 8: e73166.
26. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW,. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289: 1107-1116.
27. Al-Olah YH, Al Thiab KM,. Admissions through the emergency department due to drug-related problems. Ann Saudi Med 2008; 28: 426-429.
28. Zargarzadeh AH, Emami MH, Hosseini F,. Drug-related hospital admissions in a generic pharmaceutical system. Clin Exp Pharmacol Physiol 2007; 34: 494-498.
29. Raschetti R, Morgutti M, Menniti-Ippolito F, Belisari A, Rossignoli A, Longhini P, La Guidara C,. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54: 959-963.
30. Franceschi A, Tuccori M, Bocci G, Vannozzi F, Di Paolo A, Barbara C, Lastella M, Blandizzi C, Del Tacca M,. Drug therapeutic failures in emergency department patients. A university hospital experience. Pharmacol Res 2004; 49: 85-91.
31. Roughead EE,. The nature and extent of drug-related hospitalisations in Australia. J Qual Clin Pract 1999; 19: 19-22.
32. Hallas J, Gram LF, Grodum E, Damsbo N, Brosen K, Haghfelt T, Harvald B, Beck-Nielsen J, Worm J, Jensen KB,. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61-68.
33. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW,. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13: 306-314.
34. Edwards IR, Aronson JK,. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
35. Goettler M, Schneeweiss S, Hasford J,. Adverse drug reaction monitoring-Cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6: (Suppl. 3): S79-90.
36. World Health Organization. Technical Report Series. International Drug Monitoring: The Role of National Centres. Geneva: World Health Organization, 1972.
37. van Gijssel-Wiersma DG, van den Bemt PM, Walenbergh-van Veen MC,. Influence of computerised medication charts on medication errors in a hospital. Drug Saf 2005; 28: 1119-1129.
38. Compton WM, Thomas YF, Stinson FS, Grant BF,. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2007; 64: 566-576.
39. Jönsson AK, Spigset O, Tjäderborn M, Druid H, Hägg S,. Fatal drug poisonings in a Swedish general population. BMC Clin Pharmacol 2009; 9: 7.
40. Hallas J, Harvald B, Worm J, Beck-Nielsen J, Gram LF, Grodum E, Damsbo N, Schou J, Kromann-Andersen H, Frolund F,. Drug related hospital admissions: results from an intervention program. Eur J Clin Pharmacol 1993; 45: 199-203.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edn. Washington DC: American Psychiatric Association, 2000.
42. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, Damsbo N,. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228: 83-90.
43. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M,. The new Swedish Prescribed Drug Register-Opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
44. Wirehn AB, Karlsson HM, Carstensen JM,. Estimating disease prevalence using a population-based administrative healthcare database. Scand J Public Health 2007; 35: 424-431.
45. Östergötland County Council. Annual Report 2008. [in Swedish], Linköping: Östergötland County Council, 2009.
46. Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjo ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B,. SFINX-A drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009; 65: 627-633.
47. Howard RL, Avery AJ, Howard PD, Partridge M,. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003; 12: 280-285.
48. National Board of Health and Welfare. Public Health Report. [In Swedish], Västerås: National Board of Health and Welfare, 2009.
49. World Health Organization. Guidelines for ATC Classification and DDD Assignment 2010. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2009.
50. Medical Dictionary for Regulatory Activities. Introductory Guide MedDRA Version 14.0, document MSSO-DI-6003-14.0.0, Geneva: Medical Dictionary for Regulatory Activities, 2011.
51. Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S,. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf 2012; 35: 105-126.
52. Ferner RE, Aronson JK,. Preventability of drug-related harms-Part I: a systematic review. Drug Saf 2010; 33: 985-994.
53. Agbabiaka TB, Savovic J, Ernst E,. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008; 31: 21-37.
54. Kunac DL, Reith DM, Kennedy J, Austin NC, Williams SM,. Inter- and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care 2006; 15: 196-201.
55. Hanlon JT, Schmader KE, Koronkowski MJ, Weinberger M, Landsman PB, Samsa GP, Lewis IK,. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45: 945-948.
56. Weissman JS, Schneider EC, Weingart SN, Epstein AM, David-Kasdan J, Feibelmann S, Annas CL, Ridley N, Kirle L, Gatsonis C,. Comparing patient-reported hospital adverse events with medical record review: do patients know something that hospitals do not? Ann Intern Med 2008; 149: 100-108.
57. Gyllensten H, Hakkarainen KM, Jönsson AK, Andersson Sundell K, Hägg S, Rehnberg C, Carlsten A,. Modelling drug-related morbidity in Sweden using an expert panel of pharmacists. Int J Clin Pharmacol 2012; 34: 538-546.
58. Johnson JA, Bootman JL,. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med 1995; 155: 1949-1956.
59. Hakkarainen KM, Alström D, Hägg S, Carlsten A, Gyllensten H,. Modelling drug-related morbidity in Sweden using an expert panel of physicians. Eur J Clin Pharmacol 2012; 68: 1309-1319.
60. Wiffen P, Gill M, Edwards J, Moore A,. Adverse drug reactions in hospital patients-A systematic review of the prospective and retrospective studies. Bandolier Extra 2002; June: 1-16.
61. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM,. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18-820 patients. BMJ 2004; 329: 15-19.
62. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M,. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009; 4: e4439.
63. Cuijpers P,. The patient perspective in research on major depression. BMC Psychiatry 2011; 11: 89.
64. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ,. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-1841.
65. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M,. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63: 136-147.
66. Pintor-Marmol A, Baena MI, Fajardo PC, Sabater-Hernandez D, Saez-Benito L, Garcia-Cardenas MV, Fikri-Benbrahim N, Azpilicueta I, Faus MJ,. Terms used in patient safety related to medication: a literature review. Pharmacoepidemiol Drug Saf 2012; 21: 799-809.
67. Yu KH, Nation RL, Dooley MJ,. Multiplicity of medication safety terms, definitions and functional meanings: when is enough enough? Qual Saf Health Care 2005; 14: 358-363.
68. Danielsson M, Talback M,. Public health: an overview: health in Sweden: the National Public Health Report 2012. Chapter 1. Scand J Public Health 2012; 40: 6-22.
69. Weitoft GR, Ericsson O, Fastbom J,. Prescription drugs: health in Sweden: the National Public Health Report 2012. Chapter 18. Scand J Public Health 2012; 40: 293-304.
70. Anell A, Glenngård AH, Merkur S,. Sweden: health system review. Health Syst Transit 2012; 14: 1-159.
71. Organisation for Economic Co-operation and Development. Health care quality indicators project: patient safety indicators report 2009 (OECD Health Working Paper No. 47), Paris: Organisation for Economic Co-operation and Development, 2009.
72. Runciman WB, Edmonds MJ, Pradhan M,. Setting priorities for patient safety. Qual Saf Health Care 2002; 11: 224-229.
73. Gyllensten H, Rehnberg C, Jönsson AK, Petzold M, Carlsten A, Andersson Sundell K,. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open 2013; 3: e002574.
74. Vincent C,. High performing healthcare systems. In: Patient Safety, 2nd edn. ed., Vincent C,. West Sussex: Wiley-Blackwell, 2010; 390-404.
75. Nolan TW,. System changes to improve patient safety. BMJ 2000; 320: 771-773.
76. Leape LL,. System analysis and redesign: the foundation of medical error prevention. In: Medication Errors, 2nd edn. ed., Cohen MR,. Washington DC: American Pharmacists' Association, 2006; 3-14.